Typical neoantigen prediction pipelines involve whole-exome sequencing variant calling between tumor and matched-normal samples, RNA sequencing (RNA-seq) quantification of highly expressed tumor-specific mutations and prioritizing mutation derived neo-epitopes using (among other methods) predicted binding affinities to MHC molecules expressed by the patient (Hundal et al., 2016; Kardos et al., 2016; Kim et al., 2018; Ott et al., 2017; Rajasagi et al., 2014; Sahin et al., 2017; Smith et al., 2019; 2019; Turajlic et al., 2017; Yarchoan et al., 2017). Here, HLA-C is linked to neoplasm.